News room

Egetis is an innovative and integrated pharmaceutical company, focusing on projects in late-stage development for commercialization for treatments of serious diseases with significant unmet medical needs in the orphan drug segment

Resolutions from extraordinary general meeting in PledPharma AB (publ) held on 11 December 2020

December 11, 2020

The extraordinary general meeting in PledPharma AB (publ) (“PledPharma” or the “Company”) was held today on 11 December 2020, where the general meeting resolved in accordance with submitted proposals. The complete proposals are set out in the notice to the general meeting.

The general meeting resolved among others to adopt a new articles of association so that sections 1 (name), 3 (object of the company’s business), 4 (share capital), 5 (number of shares) and 8 (notification of and the right of participation in shareholders’ meeting) were amended.
Following registration of the new articles of association with the Swedish Companies Registration Office, the Company’s name will change to Egetis Therapeutics AB (publ).

Share

Twitter
LinkedIn

Contact us

Address: Klara Norra Kyrkogata 26, SE 111 22 Stockholm, Sweden

Phone: +46 8 679 72 10

E-mail: info@egetis.com